Insights & news

Novartis Settles Bribery Charges under Foreign Corrupt Practices Act in Relation to Medicine-Related Conduct in Greece

  • 26/06/2020
  • News

Novartis AG, its subsidiary Novartis Hellas S.A.C.I., and its former subsidiary Alcon Pte Ltd (together Novartis) have agreed to pay total fines in excess of US $ 345 million to settle cases started by the US Department of Justice (the DOJ) and the US Securities and Exchange Commission (the SEC) under the US Foreign Corrupt Practices Act (FCPA) (see, attached press releases of 25 June 2020). A significant part of the practices alleged to be in violation of the FCPA took place in Greece.
 
Novartis was under investigation because it had made illicit payments to employees of state-owned or state-controlled health institutions in Greece and had also mischaracterised and falsely recorded these payments in its company books and accounts. For the US agencies, these payments amounted to bribery and their false characterisation as an attempt to cover up a crime.
 
The case serves as a reminder that conduct in Europe engaged in by a European firm and possibly in violation of European pharmaceutical and anti-bribery rules may also give rise to extensive exposure under US anti-corruption laws.
 
Novartis admitted that, between 2012 and 2015, it bribed healthcare professionals in Greece in an attempt to increase the sale of Novartis-branded pharmaceutical products.  Specifically, Novartis allowed healthcare professionals to travel overseas to medical congresses, including events held in the United States, in exchange for an assurance that these healthcare professionals would augment the number of prescriptions for Lucentis, a prescription-only ophthalmological medicine.  
Novartis also admitted that, between 2009 and 2010, it made improper payments to healthcare professionals in connection with an epidemiological study that was intended to increase sales of Novartis-branded prescription medicines. Novartis staff recognised that many participating healthcare professionals understood that they were being paid in exchange for writing prescriptions of Novartis products and not for supplying data as part of a clinical study.

Novartis not only agreed to pay sizeable fines, it also committed to cooperate with the US government in pending or future connected criminal investigations. Additionally, Novartis promised to enhance its compliance programmes, report on the implementation of enhanced compliance programmes, and take other remediation steps.

 

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *